openPR Logo
Press release

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016

04-24-2017 06:49 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Partnerships, Licensing, Investments and M&A Deals and Trends

ReportsWorldwide has announced the addition of a new report title Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016 to its growing collection of premium market research reports.

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q4 2016 with 986 deals worth USD81.7 billion, as compared 1,194 worth USD85.9 billion in Q4 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q4 2016, when compared to 1,009 deals worth USD112.6 billion in Q3 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD1 billion in Q4 2016, as compared USD1.6 billion in Q4 2015. On a quarter-on-quarter basis, the upfront payments reported an increase in Q4 2016, when compared to USD589.2m in Q3 2016. Deals in oncology therapeutics market registered an increase with 339 deals in Q4 2016, compared to 330 deals in Q3 2016. North America registered a decrease in the number of deals with 630 deals in Q4 2016, compared to 690 deals in Q3 2016.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=33742

Scopes

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/partnerships-licensing-investments-and-ma-deals-and-trends-in-pharmaceuticals-q4-2016

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016 here

News-ID: 512888 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for M&A

industrials m&a,m&a project management,corporate finance mergers and acquisition …
Mergers and acquisitions (M&A) in the industrial sector refer to the process of one company acquiring another company or assets in the manufacturing, construction, and engineering industries. The industrial sector is characterized by a diverse range of businesses, including heavy machinery, aerospace, and defense, chemicals, and engineering services. https://upworkservice.com/ China M&A advisory E-mail:nolan@pandacuads.com The industrial sector is characterized by a high level of consolidation, with companies looking to acquire other companies to gain access
m&a company,m&a integration,cross border merger,m&a due diligence,m&a strategy,m …
Mergers and acquisitions (M&A) are a common way for companies to grow and diversify their business operations. The process of merging or acquiring another company can be complex and time-consuming, but when executed successfully, it can bring significant benefits to the acquiring company, such as access to new markets, technologies, and customers. https://upworkservice.com China M&A advisory E-mail:nolan@pandacuads.com When it comes to successful M&A, the key is to ensure that the two companies are a
private equity m&a,international mergers and acquisitions,technology m&a,m&a pro …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. One type of buyer that is becoming increasingly prevalent in the M&A landscape is private equity firms. https://upworkservice.com/ China M&A advisory E-mail:nolan@pandacuads.com Private equity firms are investment firms that raise capital from institutional investors and high net
buy side m&a,global m&a,bank mergers and acquisitions,m&a advisory firms,success …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. The term "buy side" refers to the party that is acquiring the target company. In contrast, the "sell side" refers to the party that is being acquired. https://upworkservice.com/ China M&A advisory E-mail:nolan@pandacuads.com The buy side M&A process
due diligence in mergers and acquisitions,recent m&a deals 2023,m&a management,m …
Due diligence is an investigation process that companies undertake prior to a merger or acquisition (M&A) in order to assess the target company's financial and operational condition. The goal of due diligence is to identify any potential risks or opportunities that may impact the value of the acquisition and to ensure that the deal is in the best interest of the acquiring company. Due diligence is a critical step in
m&a valuation,corporate mergers,m&a business,merger integration,sell side m&a pr …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. One crucial aspect of the M&A process is the valuation of the target company. Valuation is the process of determining the fair value of a company, and it is an essential step in the M&A process because it helps companies to determine the terms of the acquisition, such